Virgil E.J.C. Schijns – författare
Visar alla böcker från författaren Virgil E.J.C. Schijns. Handla med fri frakt och snabb leverans.
2 produkter
2 produkter
2 159 kr
Skickas inom 10-15 vardagar
Immunopotentiators in Modern Vaccines provides an in-depth insight and overview of a number of most promising immunopotentiators in modern vaccines. In contrast to existing books on the subject it provides recent data on the critical mechanisms governing the activity of vaccine adjuvants and delivery systems. Knowledge of immunological pathways and scenarios of the cells and molecules involved is described and depicted in comprehensive illustrations. Contributions from leading international authorities in the field Well-illustrated, informative figures present the interactions between immunopotentiators and the host immune system Each chapter lists advantages and potential hurdles for achieving a practical application for the specific immunopentiator
1 394 kr
Skickas inom 7-10 vardagar
Immunopotentiators in Modern Vaccines, Second Edition, provides in-depth insights and overviews of the most successful adjuvants, those that have been included in licensed products, also covering the most promising technologies that have emerged in recent years. In contrast to existing books on the subject, the chapters here provide summaries of key data on the mechanisms of action of the individual vaccine adjuvants.
In addition, the book covers key aspects of how the technologies might be further developed and what might be their limitations, while also giving an overview of what made the most advanced adjuvant technologies successful.
Provides contributions from leading international authorities in the field Features immunopotentiators classified by function, with well-illustrated, informative figures presenting the interaction between the immunopotentiators and the host immune system Lists advantages and potential hurdles for achieving a practical application for each specific immunopotentiator Offers US FDA perspectives which highlight how future adjuvants will be approved for new generation vaccines